TellBio, Inc., a biotechnology company specializing in cancer detection, has recently published two manuscripts that highlight the potential applications of its TellDx platform in prostate cancer and advanced breast cancer. The papers, titled "DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and circulating tumor cells" and "Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells," were featured in Cell and Breast Cancer Research and Treatment, respectively.
These publications showcase how TellDx technology can be utilized in various clinical settings, ranging from early localized disease to advanced metastatic disease. By analyzing circulating tumor cells (CTCs) isolated with TellDx, valuable insights into cancer progression can be obtained, which can then inform therapeutic decision-making.
In the Cell publication, researchers identified specific large DNA domains that consistently exhibited hypomethylation in both prostate CTCs and tumors. This hypomethylation was found to silence genes related to the immune system while sparing genes involved in cell proliferation. As a result, tumor growth was enabled.